The clinical AD response develops slowly over the first weeks of treatment, and one explanation for this delayed response may be the need for physical growth and reorganization in the brain, responses that are mediated by BDNF signaling and downstream pathway events [2]. Here, BDNF is linked to Alzheimer disease.